tradmap

TEVA Earnings Teva Pharmaceutical Industries Ltd

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$16 -$8 $1 $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $11B $22B 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$16B -$7B $1B $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $2B $5B Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$846M -$183M $480M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–53 of 53
Q2 20262026-06-30-0.492026-07-2910-Q
Q1 20262026-03-310.312026-04-2910-Q
Q4 2025 (derived)2025-12-310.422026-02-0310-K
FY 20252025-12-311.212026-02-0310-K
Q3 20252025-09-300.372025-11-0510-Q
Q2 20252025-06-300.242025-07-3010-Q
Q1 20252025-03-310.182025-05-0710-Q
Q4 2024 (derived)2024-12-31-0.192025-02-0510-K
FY 20242024-12-31-1.452025-02-0510-K
Q3 20242024-09-30-0.392024-11-0610-Q
Q2 20242024-06-30-0.752024-07-3110-Q
Q1 20242024-03-31-0.122024-05-0810-Q
Q4 2023 (derived)2023-12-310.422024-02-1210-K
FY 20232023-12-31-0.502024-02-1210-K
Q3 20232023-09-300.062023-11-0910-Q
Q2 20232023-06-30-0.782023-08-0210-Q
Q1 20232023-03-31-0.202023-05-1010-Q
Q4 20222022-12-31-1.17——
FY 20222022-12-31-2.202023-02-1010-K
Q3 20222022-09-300.052022-11-0310-Q
Q2 20222022-06-30-0.232022-07-2710-Q
Q1 20222022-03-31-0.862022-05-0310-Q
Q4 2021 (derived)2021-12-31-0.142022-02-0910-K
FY 20212021-12-310.382022-02-0910-K
Q3 20212021-09-300.262021-10-2710-Q
Q2 20212021-06-300.192021-07-2810-Q
Q1 20212021-03-310.072021-04-2810-Q
Q4 20202020-12-310.142021-02-1010-K
FY 20202020-12-31-3.642021-02-1010-K
Q3 20202020-09-30-3.972020-11-0510-Q
Q2 20202020-06-300.132020-08-0510-Q
Q1 20202020-03-310.062020-05-0710-Q
Q4 20192019-12-310.102020-02-2110-K
FY 20192019-12-31-0.912020-02-2110-K
Q3 20192019-09-30-0.292019-11-0710-Q
Q2 20192019-06-30-0.632019-08-0710-Q
Q1 20192019-03-31-0.102019-05-0210-Q
Q4 20182018-12-31-2.852019-02-1910-K
FY 20182018-12-31-2.352019-02-1910-K
Q3 20182018-09-30-0.272018-11-0110-Q
Q2 20182018-06-30-0.242018-08-0210-Q
Q1 20182018-03-311.032018-05-0310-Q
Q4 20172017-12-31-11.412018-02-1210-K
FY 20172017-12-31-16.262018-02-1210-K
Q3 20172017-09-300.52——
Q2 20172017-06-30-5.94——
Q1 20172017-03-310.57——
Q4 20162016-12-31-1.02——
FY 20162016-12-310.07——
Q3 20162016-09-300.35——
Q2 20162016-06-300.20——
Q1 20162016-03-310.62——
FY 20152015-12-311.82——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.